Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan
Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.